Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.61 |
| ▸ | CES1 | P23141 | 1/20 | 0.61 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 6/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28141435 | 0.97 | CES2 (0.65) | CES2CES1HDAC8HDAC6TSHR | |
| SCHEMBL993393 | 0.97 | CES2 (0.65) | CES2CES1HDAC8HDAC6TSHR | |
| SCHEMBL27542869 | 0.97 | CES2 (0.65) | CES2CES1HDAC8HDAC6TSHR | |
| SCHEMBL6937404 | 0.97 | CES2 (0.65) | CES2CES1HDAC8HDAC6TSHR | |
| SCHEMBL6141408 | 0.97 | CES2 (0.56) | CES2CES1HDAC8HDAC6TSHR | |
| SCHEMBL31486636 | 0.97 | CES2 (0.65) | CES2CES1HDAC8HDAC6TSHR | |
| SCHEMBL346017 | 0.97 | CES2 (0.65) | CES2CES1HDAC8HDAC6TSHR | |
| SCHEMBL9861947 | 0.97 | CES2 (0.65) | CES2CES1HDAC8HDAC6TSHR | |
| SCHEMBL27502916 | 0.97 | CES2 (0.65) | CES2CES1HDAC8HDAC6TSHR | |
| SCHEMBL9259378 | 0.97 | CES2 (0.65) | CES2CES1HDAC8HDAC6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5763627-A | Process for preparing cyclopropyl alkyl ketones and 4,5-dihydroalkyfurans | HUELS AKTIENGESELLSCHAFT (DE) | 1998-06-09 | — | — | US | claimed |
| US-20240174698-A1 | MODULAR SYNTHESIS OF 1,2-AZABORINES VIA RING-OPENING BN-ISOSTERE BENZANNULATION | THE UNIVERSITY OF CHICAGO | 2024-05-30 | — | — | US | disclosed |
| EP-1517881-A1 | 4-(3,3-DIHALO-ALLYLOXY)PHENOXY ALKYL DERIVATIVES | Syngenta Participations AG (CH) | 2005-03-30 | — | — | EP | disclosed |
| WO-2004002943-A1 | 4-(3,3-DIHALO-ALLYLOXY)PHENOXY ALKYL DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2004-01-08 | — | — | WO | disclosed |
| EP-0820977-B1 | Process for the preparation of cyclopropylalkylketones and 4,5-dihydroalkylfurans | DEGUSSA (DE) | 2000-04-26 | — | — | EP | disclosed |
| US-5763627-A | Process for preparing cyclopropyl alkyl ketones and 4,5-dihydroalkyfurans | HUELS AKTIENGESELLSCHAFT (DE) | 1998-06-09 | — | — | US | disclosed |
| EP-0820977-A1 | Process for the preparation of cyclopropylalkylketones and 4,5-dihydroalkylfurans | HÜLS AKTIENGESELLSCHAFT (DE) | 1998-01-28 | — | — | EP | disclosed |
| EP-0725066-B1 | Process for the production of cyclopropylalkylketones and 4,5-dihydroalkylfuranes | HUELS CHEMISCHE WERKE AG (DE) | 1997-07-16 | — | — | EP | disclosed |
| US-5629455-A | Process for preparing cyclopropyl alkyl ketones and 4,5-dihydroalkylfurans | HUELS AKTIENGESELLSCHAFT (DE) | 1997-05-13 | — | — | US | disclosed |
| EP-0725066-A1 | Process for the production of cyclopropylalkylketones and 4,5-dihydroalkylfuranes | HÜLS AKTIENGESELLSCHAFT (DE) | 1996-08-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174698-A1 | MODULAR SYNTHESIS OF 1,2-AZABORINES VIA RING-OPENING BN-ISOSTERE BENZANNULATION | NBAS, DBF4, ALKBH2 | CES2 2769/4885CES1 4199/4885HDAC8 3575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.